1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  05/20 02:00:00 am EDT
3536.00 JPY   +0.31%
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
AQ
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indications of Refractory Pemphigus Vulgaris and Pemphigus Foliaceus

12/24/2021 | 03:07am EDT

Zenyaku Kogyo Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Anti-CD20 Monoclonal Antibody Rituxan

Approved for Additional Indications of

Refractory Pemphigus Vulgaris and Pemphigus Foliaceus

TOKYO, December 24, 2021 --Zenyaku Kogyo Co., Ltd.(Japanese-only website) and Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced today that Zenyaku obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for an anti-CD20 monoclonal antibody Rituxan® injection 100 mg and 500 mg [generic name: rituximab (genetical recombination)] (hereafter, "Rituxan") for additional indications of refractory pemphigus vulgaris and pemphigus foliaceus. Rituxan is co-marketed by the two companies in Japan.

Rituxan is an anti-CD20 monoclonal antibody that specifically binds to CD20 antigen, a protein expressed on B cells. It attacks target B cells using the immune system equipped with the human body, and damages cells. This approval is based on the results of an investigator-initiated phase

  1. clinical trial in Japan in patients with pemphigus inadequately responding to steroidal treatment (KCTR-D006 study) led by Keio University Hospital, and an overseas phase III clinical trial (PEMPHIX study) conducted by Roche.

Pemphigus is an autoimmune bullous disease that affects the skin and mucous membranes. Pemphigus vulgaris is the most common subtype in Japan, followed by pemphigus foliaceus. The male-to-female ratio is 1:1.5, more often in female, and the peak age of onset is 50 to 69.The main clinical features are painful and intractable erosions and ulcers in the oral mucosa, which may result in poor feeding in severe cases. Also, stratified squamous epithelium, including lips, pharynx, larynx, esophageal, palpebral conjunctiva, and vagina may be damaged, which can cause flaccid blisters and erosions in the skin in about half of the cases.1) Approximately 3,000 patients with pemphigus are reported in Japan2), among which about 500 patients are with refractory pemphigus and eligible for Rituxan.3) Pemphigus has been designated as an intractable disease by the Ministry of Health, Labour and Welfare (designated intractable disease 35).4)

Zenyaku and Chugai will continue working closely together so that Rituxan may contribute to the treatment of refractory pemphigus vulgaris and pemphigus foliaceus.

Trademarks used or mentioned in this release are protected by law.

Sources

  1. Masayuki Amagai, Akiko Tanikawa, Tomoko Shimizu, et al. Japanese guidelines for the management of pemphigus. The Japanese Journal of Dermatology. 2010;120(7): 1443-1460
  2. Japan Intractable Diseases Information Center. Number of holders of specific medical expenses (designated intractable disease) beneficiary certificate (as of the end of the first fiscal year of Reiwa. https://www.nanbyou.or.jp/entry/5354. Accessed December 2021 (Japanese only)
  3. 4th round development request for unapproved drugs/indications with high medical need (Request No. IV-7).https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000112749.pdf. Accessed December 2021 (Japanese only)
  4. Japan Intractable Diseases Information Center. Pemphigus (designated intractable disease 35) https://www.nanbyou.or.jp/entry/153. Accessed December 2021 (Japanese only)

Contact:

Zenyaku Kogyo Co., Ltd.

Chugai Pharmaceutical Co., Ltd.,

General Affairs and Personnel Dept.,

Corporate Communications Dept.,

Public Relations and Secretarial Section

Media Relations Group

Tel: +81-3-3946-1120

Tel: +81-3-3273-0881

Investor Relations Group

Tel: +81-3-3273-0554

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 24 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 December 2021 08:06:06 UTC.


© Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares a..
AQ
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted ..
PU
04/26CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
04/26Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes
AQ
04/26Nikkei 225 Up 0.4% on Wall Street Cues, Softer Interest Rates, Oil Outlook
MT
04/26Chugai Pharmaceutical Logs 178% Surge in Q1 Net Income on Higher Sales
MT
04/25CHUGAI PHARMACEUTICAL : 1Q Results (Jan-Mar 2022)
PU
04/25Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces First Quarter Sales 20..
AQ
04/25CHUGAI PHARMACEUTICAL : Supplementary Materials for Consolidated Financial Results for the..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 187 B 9 282 M 9 282 M
Net income 2022 343 B 2 679 M 2 679 M
Net cash 2022 604 B 4 723 M 4 723 M
P/E ratio 2022 17,0x
Yield 2022 2,20%
Capitalization 5 815 B 45 478 M 45 478 M
EV / Sales 2022 4,39x
EV / Sales 2023 4,88x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 536,00 JPY
Average target price 4 677,69 JPY
Spread / Average Target 32,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-5.33%45 478
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707